Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer

H. Kusumoto, Yoshihiko Maehara, T. Kusumoto, H. Anai, K. Akazawa, K. Sugimachi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.

Original languageEnglish
Pages (from-to)685-689
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume14
Issue number6
Publication statusPublished - Dec 1 1988

Fingerprint

Carbazilquinone
Stomach Neoplasms
Mitomycin
Doxorubicin
Pharmaceutical Preparations
Lymph Nodes
Neoplasm Metastasis
Fluorouracil
Liver
Aclarubicin
Neoplasms
Succinate Dehydrogenase
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Kusumoto, H., Maehara, Y., Kusumoto, T., Anai, H., Akazawa, K., & Sugimachi, K. (1988). Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. European Journal of Surgical Oncology, 14(6), 685-689.

Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. / Kusumoto, H.; Maehara, Yoshihiko; Kusumoto, T.; Anai, H.; Akazawa, K.; Sugimachi, K.

In: European Journal of Surgical Oncology, Vol. 14, No. 6, 01.12.1988, p. 685-689.

Research output: Contribution to journalArticle

Kusumoto, H, Maehara, Y, Kusumoto, T, Anai, H, Akazawa, K & Sugimachi, K 1988, 'Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer', European Journal of Surgical Oncology, vol. 14, no. 6, pp. 685-689.
Kusumoto H, Maehara Y, Kusumoto T, Anai H, Akazawa K, Sugimachi K. Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. European Journal of Surgical Oncology. 1988 Dec 1;14(6):685-689.
Kusumoto, H. ; Maehara, Yoshihiko ; Kusumoto, T. ; Anai, H. ; Akazawa, K. ; Sugimachi, K. / Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. In: European Journal of Surgical Oncology. 1988 ; Vol. 14, No. 6. pp. 685-689.
@article{7e59cb16e1984f6893c82579ddfc0c88,
title = "Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer",
abstract = "An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.",
author = "H. Kusumoto and Yoshihiko Maehara and T. Kusumoto and H. Anai and K. Akazawa and K. Sugimachi",
year = "1988",
month = "12",
day = "1",
language = "English",
volume = "14",
pages = "685--689",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer

AU - Kusumoto, H.

AU - Maehara, Yoshihiko

AU - Kusumoto, T.

AU - Anai, H.

AU - Akazawa, K.

AU - Sugimachi, K.

PY - 1988/12/1

Y1 - 1988/12/1

N2 - An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.

AB - An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.

UR - http://www.scopus.com/inward/record.url?scp=0024236081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024236081&partnerID=8YFLogxK

M3 - Article

C2 - 3192005

AN - SCOPUS:0024236081

VL - 14

SP - 685

EP - 689

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 6

ER -